Information  X 
Enter a valid email address

Futura Medical PLC (FUM)

  Print      Mail a friend       Annual reports

Friday 01 February, 2019

Futura Medical PLC

Total Voting Rights

RNS Number : 7519O
Futura Medical PLC
01 February 2019
 

 

 

Futura Medical plc

("Futura" or "the Company")

Total Voting Rights

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, for the purposes of the FCA's Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 204,660,267 Ordinary Shares.

Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is 204,660,267 and this figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information please contact:           

For media enquiries please contact:

 

 

Futura Medical plc

Optimum Strategic Communications

Angela Hildreth, FD/COO

Mary Clark/ Hollie Vile/ Ellie Blackwell              

[email protected]

Email: [email protected]

www.futuramedical.com

Tel: +44 (0) 203 950 9144

Tel: +44 (0) 1483 685 670

 

 

 

Nominated Advisor/Broker

 

N+1 Singer

 

Aubrey Powell/ Ben Farrow (Corporate Finance)

 

Tom Salvesen/ Mia Gardner (Corporate Broking)

 

Tel: +44 (0) 20 7496 3000

 

 

Notes to Editors

 

Futura Medical plc

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TVRZMGFMNMVGLZM

a d v e r t i s e m e n t